There were 1,560 press releases posted in the last 24 hours and 413,979 in the last 365 days.

New Research Coverage Highlights Amarin, Corbus Pharmaceuticals, Green Brick Partners, Immutep, Texas Capital Bancshares, and G1 THERAPEUTICS — Consolidated Revenues, Company Growth, and Expectations for 2018

NEW YORK, March 16, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Amarin Corporation PLC (NASDAQ:AMRN), Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), Green Brick Partners, Inc. (NASDAQ:GRBK), Immutep Limited (NASDAQ:IMMP), Texas Capital Bancshares, Inc. (NASDAQ:TCBI), and G1 THERAPEUTICS (NASDAQ:GTHX), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

AMRN DOWNLOAD: http://Fundamental-Markets.com/register/?so=AMRN
CRBP DOWNLOAD: http://Fundamental-Markets.com/register/?so=CRBP
GRBK DOWNLOAD: http://Fundamental-Markets.com/register/?so=GRBK
IMMP DOWNLOAD: http://Fundamental-Markets.com/register/?so=IMMP
TCBI DOWNLOAD: http://Fundamental-Markets.com/register/?so=TCBI
GTHX DOWNLOAD: http://Fundamental-Markets.com/register/?so=GTHX

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Fundamental Markets, available for free download at the links above, examine Amarin Corporation PLC (NASDAQ:AMRN), Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), Green Brick Partners, Inc. (NASDAQ:GRBK), Immutep Limited (NASDAQ:IMMP), Texas Capital Bancshares, Inc. (NASDAQ:TCBI), and G1 THERAPEUTICS (NASDAQ:GTHX) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed March 14th, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

AMARIN CORPORATION PLC (AMRN) REPORT OVERVIEW

Amarin's Recent Financial Performance

For the three months ended December 31st, 2017 vs December 31st, 2016, Amarin reported revenue of $53.87MM vs $38.70MM (up 39.20%) and basic earnings per share -$0.08 vs -$0.10. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Amarin reported revenue of $181.10MM vs $130.08MM (up 39.22%) and basic earnings per share -$0.25 vs -$0.41. Amarin is expected to report earnings on May 2nd, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was -$0.08. The estimated EPS forecast for the next fiscal year is $0.11 and is expected to report on February 26th, 2019.

To read the full Amarin Corporation PLC (AMRN) report, download it here: http://Fundamental-Markets.com/register/?so=AMRN

-----------------------------------------

CORBUS PHARMACEUTICALS HOLDINGS, INC. (CRBP) REPORT OVERVIEW

Corbus Pharmaceuticals' Recent Financial Performance

For the three months ended December 31st, 2017 vs December 31st, 2016, Corbus Pharmaceuticals reported revenue of $0.00MM vs $0.38MM and basic earnings per share -$0.20 vs -$0.18. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Corbus Pharmaceuticals reported revenue of $2.44MM vs $1.91MM (up 27.67%) and basic earnings per share -$0.65 vs -$0.49. Corbus Pharmaceuticals is expected to report earnings on May 8th, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was -$0.16. The estimated EPS forecast for the next fiscal year is -$1.07 and is expected to report on March 11th, 2019.

To read the full Corbus Pharmaceuticals Holdings, Inc. (CRBP) report, download it here: http://Fundamental-Markets.com/register/?so=CRBP

-----------------------------------------

GREEN BRICK PARTNERS, INC. (GRBK) REPORT OVERVIEW

Green Brick Partners' Recent Financial Performance

For the three months ended December 31st, 2017 vs December 31st, 2016, Green Brick Partners reported revenue of $136.38MM vs $119.76MM (up 13.87%) and basic earnings per share -$0.18 vs $0.16. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Green Brick Partners reported revenue of $454.37MM vs $380.33MM (up 19.47%) and basic earnings per share $0.30 vs $0.49 (down 38.78%). Green Brick Partners is expected to report earnings on May 14th, 2018. The report will be for the fiscal period ending March 31st, 2018.

To read the full Green Brick Partners, Inc. (GRBK) report, download it here: http://Fundamental-Markets.com/register/?so=GRBK

-----------------------------------------

IMMUTEP LIMITED (IMMP) REPORT OVERVIEW

Immutep's Recent Financial Performance

For the twelve months ended June 30th, 2017 vs June 30th, 2016, Immutep reported revenue of $3.18MM vs $1.48MM (up 115.29%) and basic earnings per share -$0.30 vs -$2.02.

To read the full Immutep Limited (IMMP) report, download it here: http://Fundamental-Markets.com/register/?so=IMMP

-----------------------------------------

TEXAS CAPITAL BANCSHARES, INC. (TCBI) REPORT OVERVIEW

Texas Capital Bancshares' Recent Financial Performance

For the three months ended December 31st, 2017 vs December 31st, 2016, Texas Capital Bancshares reported interest income of $249.52MM vs $188.67MM (up 32.25%) and basic earnings per share $0.86 vs $0.98 (down 12.24%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Texas Capital Bancshares reported interest income of $879.30MM vs $703.41MM (up 25.01%) and basic earnings per share $3.78 vs $3.14 (up 20.38%). Texas Capital Bancshares is expected to report earnings on April 18th, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was $0.80. The estimated EPS forecast for the next fiscal year is $6.78 and is expected to report on January 23rd, 2019.

To read the full Texas Capital Bancshares, Inc. (TCBI) report, download it here: http://Fundamental-Markets.com/register/?so=TCBI

-----------------------------------------

G1 THERAPEUTICS (GTHX) REPORT OVERVIEW

G1 THERAPEUTICS's Recent Financial Performance

G1 THERAPEUTICS is expected to report earnings on May 16th, 2018. The report will be for the fiscal period ending March 31st, 2018. The estimated EPS forecast for the next fiscal year is -$2.84 and is expected to report on February 20th, 2019.

To read the full G1 THERAPEUTICS (GTHX) report, download it here: http://Fundamental-Markets.com/register/?so=GTHX

-----------------------------------------

ABOUT FUNDAMENTAL MARKETS

Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.

REGISTERED MEMBER STATUS

Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at compliance@Fundamental-Markets.com.

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact:
Andrew Duffie, Media Department
Office: +1 667-401-0010
E-mail: media@Fundamental-Markets.com

© 2018 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Fundamental-Markets.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.